The company was founded on computationally designed self-assembling virus-like particle technology developed at the Institute for Protein Design at University of Washington School of Medicine (Cell 2019, Preview).
The proceeds of the financing will be used to advance the company's first vaccine candidate, IVX-121, for respiratory syncytial virus for older adults through Phase 1b clinical studies.
Icosavax also announced its leadership team, board of directors and key scientific advisors.
Adam Simpson is the chief executive officer. He is also the CEO of PvP Biologics, another spinout from IPD. Previously he served as president and chief operating officer of Cypher Genomics (sold to Human Longevity), and chief business officer, Meritage Pharma (sold to Shire).
Doug Holtzman, Ph.D., MPH is the chief scientific officer. Previously, he served as vice president, Discovery, Takeda, and deputy director, Childhood Pneumonia, Bill and Melinda Gates Foundation. Prior to his work in global health he worked in a number of innovative early-stage biotechnology companies, including Millennium Pharmaceuticals (sold to Takeda) and Ironwood.
Niranjan Kanesa-thasan, M.D., MTMH, FIDSA, FASTMH is the chief medical officer and has contributed to the development of seven licensed vaccines.
Previously, he served as the clinical franchise head, GSK Vaccines; chief medical officer, Americas, Novartis Vaccines; and vice president, Medical Affairs and Pharmacovigilance, Acambis (sold to Sanofi Pasteur).
VLPs enable high-density, multivalent display of antigens in a manner that closely resembles viruses, with an important difference. VLPs contain no genetic material, so they are non-infectious and can provide a safer alternative to live-attenuated or inactivated vaccines.
Naturally occurring VLPs have delivered successful vaccines, including Gardasil and Cervarix against human papillomavirus and Engerix-B and Recombivax HB against Hepatitis B. However, VLPs have been difficult to use for the display of complex heterologous antigens, like in the case of RSV.
The company's RSV vaccine candidate, IVX-121, incorporates a stabilized prefusion F antigen licensed from NIAID/NIH (DS-Cav1; Science 2019).
Extensive preclinical studies conducted at IPD and Icosavax suggest that IVX-121 could increase the protective immunogenicity of RSV F compared to the DS-Cav1 antigen alone.
Tachi previously served as chief medical and scientific officer of Takeda Pharmaceuticals, where he was responsible for the acquisitions of Inviragen (dengue vaccine) and LigoCyte (norovirus vaccine).
The board of directors also includes Terry Gould, a partner and head of Growth Equity Investments, Adams Street Partners; Jason Hafler, the US Head of Investments at Sanofi Ventures; Eric Moessinger, a partner of NanoDimension; Mark McDade; and Adam Simpson.
Icosavax's in-licensed computationally designed VLP technology is a product of the IPD's Translational Investigator Program, which enables entrepreneurial researchers to turn their first working versions of designed proteins into commercially viable assets.
The license to this technology was negotiated with CoMotion at the University of Washington, UW's collaborative innovation hub.
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs.
The company was founded on breakthrough computationally designed virus-like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington. Icosavax is located in Seattle.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer